Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3
ABSTRACT A novel approach for treatment of enterovirus infections was characterized. Application of treatment course of consecutive alternating administration (CAA) of triple combination of enterovirus replication inhibitors in experimental infections (20 MLD50) with coxsackievirus B3 (CVB3) strains...
Gespeichert in:
| Veröffentlicht in: | Pathogens and Disease 2020-12, Vol.78 (9), p.1 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 1 |
| container_title | Pathogens and Disease |
| container_volume | 78 |
| creator | Stoyanova, Adelina Galabov, Angel S |
| description | ABSTRACT
A novel approach for treatment of enterovirus infections was characterized. Application of treatment course of consecutive alternating administration (CAA) of triple combination of enterovirus replication inhibitors in experimental infections (20 MLD50) with coxsackievirus B3 (CVB3) strains in newborn mice is presented. It was established that in infection with cardiotropic Woodruff strain the combination of pleconaril, МDL-860 and oxoglaucine (PMO) subjected to the CAA scheme, a significant protective effect was observed. Monotherapeutic courses as well as simultaneously daily applied PMO were without effect. Analogous data were observed at experimental infection with the neurotriopic Nancy strain of CVB3. Following IC50 values of virus samples taken every day from target organs of infected animals during the whole period of study, a drug-resistance was established in monotherapy with compounds-partners in the PMO combination. At courses by the treatment scheme CAA of PMO development of drug-resistance was not established, but an increased susceptibility to the effect of the inhibitor-components in the combination was proven. Toxicity of PMO applied via the CAA scheme and in the monotherapeutic courses in both healthy and CVB3 infected animals was recorded. All data obtained prove the potential of the CAA treatment scheme for development of effective chemotherapy of enterovirus infections.
Application of treatment course of consecutive alternating administration of triple combination of enterovirus replication inhibitors in experimental infections with coxsackievirus B3 strains in newborn mice is presented. |
| doi_str_mv | 10.1093/femspd/ftaa065 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_TOX</sourceid><recordid>TN_cdi_proquest_miscellaneous_2453689658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A690441228</galeid><oup_id>10.1093/femspd/ftaa065</oup_id><sourcerecordid>A690441228</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-450b46120198bca207a657594c42344b1fc4169184556de7eb2defadcbb0f7c83</originalsourceid><addsrcrecordid>eNqFkc1u1TAQhSMEolXbLUtkiQ0s0trxT5JluLqFSq3YFIld5Njj4pLYwXZa-hJ95jq6l4LYYC9sz3xnbM8pijcEnxLc0jMDU5z1mUlSYsFfFIcVZm0paPXt5V_7g-IkxlucR8NJU4vXxQGluMUVJofF49YYUAl5gzbeRVBLsneAujFBcDJZd4M6PVlnYwr56N1KSnQd7DxClkyDdc_xziVbbl2W-jsb5LjmZ784HZF16MoqQBduvQ40urfpe87_ilL9sJDxJaKP9Lh4ZeQY4WS_HhVfz7fXm8_l5ZdPF5vuslSsYqlkHA9MkPyDthmUrHAtBa95y3KaMjYQoxgRLWkY50JDDUOlwUithgGbWjX0qHi_qzsH_3OBmPrJRgXjKB34JfYV41Q0reAr-u4f9NYvuTfjStWiYZQLmqnTHXUjR-itMz73S-WpYbLKOzA2xzvRYsZIVTV_BCr4GAOYfg52kuGhJ7hf3e137vZ7d7Pg7f4dyzCBfsZ_e5mBDzvAL_P_ij0BYBaxVA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476843563</pqid></control><display><type>article</type><title>Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3</title><source>Oxford Academic Journals (Open Access)</source><creator>Stoyanova, Adelina ; Galabov, Angel S</creator><creatorcontrib>Stoyanova, Adelina ; Galabov, Angel S</creatorcontrib><description>ABSTRACT
A novel approach for treatment of enterovirus infections was characterized. Application of treatment course of consecutive alternating administration (CAA) of triple combination of enterovirus replication inhibitors in experimental infections (20 MLD50) with coxsackievirus B3 (CVB3) strains in newborn mice is presented. It was established that in infection with cardiotropic Woodruff strain the combination of pleconaril, МDL-860 and oxoglaucine (PMO) subjected to the CAA scheme, a significant protective effect was observed. Monotherapeutic courses as well as simultaneously daily applied PMO were without effect. Analogous data were observed at experimental infection with the neurotriopic Nancy strain of CVB3. Following IC50 values of virus samples taken every day from target organs of infected animals during the whole period of study, a drug-resistance was established in monotherapy with compounds-partners in the PMO combination. At courses by the treatment scheme CAA of PMO development of drug-resistance was not established, but an increased susceptibility to the effect of the inhibitor-components in the combination was proven. Toxicity of PMO applied via the CAA scheme and in the monotherapeutic courses in both healthy and CVB3 infected animals was recorded. All data obtained prove the potential of the CAA treatment scheme for development of effective chemotherapy of enterovirus infections.
Application of treatment course of consecutive alternating administration of triple combination of enterovirus replication inhibitors in experimental infections with coxsackievirus B3 strains in newborn mice is presented.</description><identifier>ISSN: 2049-632X</identifier><identifier>EISSN: 2049-632X</identifier><identifier>DOI: 10.1093/femspd/ftaa065</identifier><identifier>PMID: 33090201</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Alkaloids ; Animals ; Antiviral drugs ; Chemotherapy ; Coxsackievirus infections ; Coxsackieviruses ; Dosage and administration ; Drug resistance ; Drug therapy ; Drug therapy, Combination ; Enteroviruses ; Experimental infection ; Infections ; Organs ; Toxicity ; Viral infections</subject><ispartof>Pathogens and Disease, 2020-12, Vol.78 (9), p.1</ispartof><rights>The Author(s) 2020. Published by Oxford University Press on behalf of FEMS 2020</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.</rights><rights>COPYRIGHT 2020 Oxford University Press</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of FEMS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-450b46120198bca207a657594c42344b1fc4169184556de7eb2defadcbb0f7c83</citedby><cites>FETCH-LOGICAL-c424t-450b46120198bca207a657594c42344b1fc4169184556de7eb2defadcbb0f7c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1604,27924,27925</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/femspd/ftaa065$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33090201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stoyanova, Adelina</creatorcontrib><creatorcontrib>Galabov, Angel S</creatorcontrib><title>Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3</title><title>Pathogens and Disease</title><addtitle>Pathog Dis</addtitle><description>ABSTRACT
A novel approach for treatment of enterovirus infections was characterized. Application of treatment course of consecutive alternating administration (CAA) of triple combination of enterovirus replication inhibitors in experimental infections (20 MLD50) with coxsackievirus B3 (CVB3) strains in newborn mice is presented. It was established that in infection with cardiotropic Woodruff strain the combination of pleconaril, МDL-860 and oxoglaucine (PMO) subjected to the CAA scheme, a significant protective effect was observed. Monotherapeutic courses as well as simultaneously daily applied PMO were without effect. Analogous data were observed at experimental infection with the neurotriopic Nancy strain of CVB3. Following IC50 values of virus samples taken every day from target organs of infected animals during the whole period of study, a drug-resistance was established in monotherapy with compounds-partners in the PMO combination. At courses by the treatment scheme CAA of PMO development of drug-resistance was not established, but an increased susceptibility to the effect of the inhibitor-components in the combination was proven. Toxicity of PMO applied via the CAA scheme and in the monotherapeutic courses in both healthy and CVB3 infected animals was recorded. All data obtained prove the potential of the CAA treatment scheme for development of effective chemotherapy of enterovirus infections.
Application of treatment course of consecutive alternating administration of triple combination of enterovirus replication inhibitors in experimental infections with coxsackievirus B3 strains in newborn mice is presented.</description><subject>Alkaloids</subject><subject>Animals</subject><subject>Antiviral drugs</subject><subject>Chemotherapy</subject><subject>Coxsackievirus infections</subject><subject>Coxsackieviruses</subject><subject>Dosage and administration</subject><subject>Drug resistance</subject><subject>Drug therapy</subject><subject>Drug therapy, Combination</subject><subject>Enteroviruses</subject><subject>Experimental infection</subject><subject>Infections</subject><subject>Organs</subject><subject>Toxicity</subject><subject>Viral infections</subject><issn>2049-632X</issn><issn>2049-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkc1u1TAQhSMEolXbLUtkiQ0s0trxT5JluLqFSq3YFIld5Njj4pLYwXZa-hJ95jq6l4LYYC9sz3xnbM8pijcEnxLc0jMDU5z1mUlSYsFfFIcVZm0paPXt5V_7g-IkxlucR8NJU4vXxQGluMUVJofF49YYUAl5gzbeRVBLsneAujFBcDJZd4M6PVlnYwr56N1KSnQd7DxClkyDdc_xziVbbl2W-jsb5LjmZ784HZF16MoqQBduvQ40urfpe87_ilL9sJDxJaKP9Lh4ZeQY4WS_HhVfz7fXm8_l5ZdPF5vuslSsYqlkHA9MkPyDthmUrHAtBa95y3KaMjYQoxgRLWkY50JDDUOlwUithgGbWjX0qHi_qzsH_3OBmPrJRgXjKB34JfYV41Q0reAr-u4f9NYvuTfjStWiYZQLmqnTHXUjR-itMz73S-WpYbLKOzA2xzvRYsZIVTV_BCr4GAOYfg52kuGhJ7hf3e137vZ7d7Pg7f4dyzCBfsZ_e5mBDzvAL_P_ij0BYBaxVA</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Stoyanova, Adelina</creator><creator>Galabov, Angel S</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7T7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20201201</creationdate><title>Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3</title><author>Stoyanova, Adelina ; Galabov, Angel S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-450b46120198bca207a657594c42344b1fc4169184556de7eb2defadcbb0f7c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alkaloids</topic><topic>Animals</topic><topic>Antiviral drugs</topic><topic>Chemotherapy</topic><topic>Coxsackievirus infections</topic><topic>Coxsackieviruses</topic><topic>Dosage and administration</topic><topic>Drug resistance</topic><topic>Drug therapy</topic><topic>Drug therapy, Combination</topic><topic>Enteroviruses</topic><topic>Experimental infection</topic><topic>Infections</topic><topic>Organs</topic><topic>Toxicity</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stoyanova, Adelina</creatorcontrib><creatorcontrib>Galabov, Angel S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Pathogens and Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Stoyanova, Adelina</au><au>Galabov, Angel S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3</atitle><jtitle>Pathogens and Disease</jtitle><addtitle>Pathog Dis</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>78</volume><issue>9</issue><spage>1</spage><pages>1-</pages><issn>2049-632X</issn><eissn>2049-632X</eissn><abstract>ABSTRACT
A novel approach for treatment of enterovirus infections was characterized. Application of treatment course of consecutive alternating administration (CAA) of triple combination of enterovirus replication inhibitors in experimental infections (20 MLD50) with coxsackievirus B3 (CVB3) strains in newborn mice is presented. It was established that in infection with cardiotropic Woodruff strain the combination of pleconaril, МDL-860 and oxoglaucine (PMO) subjected to the CAA scheme, a significant protective effect was observed. Monotherapeutic courses as well as simultaneously daily applied PMO were without effect. Analogous data were observed at experimental infection with the neurotriopic Nancy strain of CVB3. Following IC50 values of virus samples taken every day from target organs of infected animals during the whole period of study, a drug-resistance was established in monotherapy with compounds-partners in the PMO combination. At courses by the treatment scheme CAA of PMO development of drug-resistance was not established, but an increased susceptibility to the effect of the inhibitor-components in the combination was proven. Toxicity of PMO applied via the CAA scheme and in the monotherapeutic courses in both healthy and CVB3 infected animals was recorded. All data obtained prove the potential of the CAA treatment scheme for development of effective chemotherapy of enterovirus infections.
Application of treatment course of consecutive alternating administration of triple combination of enterovirus replication inhibitors in experimental infections with coxsackievirus B3 strains in newborn mice is presented.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>33090201</pmid><doi>10.1093/femspd/ftaa065</doi></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 2049-632X |
| ispartof | Pathogens and Disease, 2020-12, Vol.78 (9), p.1 |
| issn | 2049-632X 2049-632X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2453689658 |
| source | Oxford Academic Journals (Open Access) |
| subjects | Alkaloids Animals Antiviral drugs Chemotherapy Coxsackievirus infections Coxsackieviruses Dosage and administration Drug resistance Drug therapy Drug therapy, Combination Enteroviruses Experimental infection Infections Organs Toxicity Viral infections |
| title | Effect of Consecutive Alternating Administration of a Triple Combination of Anti-Enteroviral Compounds in Mice Infected with Coxsackievirus B3 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T15%3A51%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Consecutive%20Alternating%20Administration%20of%20a%20Triple%20Combination%20of%20Anti-Enteroviral%20Compounds%20in%20Mice%20Infected%20with%20Coxsackievirus%20B3&rft.jtitle=Pathogens%20and%20Disease&rft.au=Stoyanova,%20Adelina&rft.date=2020-12-01&rft.volume=78&rft.issue=9&rft.spage=1&rft.pages=1-&rft.issn=2049-632X&rft.eissn=2049-632X&rft_id=info:doi/10.1093/femspd/ftaa065&rft_dat=%3Cgale_TOX%3EA690441228%3C/gale_TOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476843563&rft_id=info:pmid/33090201&rft_galeid=A690441228&rft_oup_id=10.1093/femspd/ftaa065&rfr_iscdi=true |